Personnel Information

写真a

AKIYAMA Hiroki


Job title

Project Assistant Professor
To the head of this page.▲

Graduating School 【 display / non-display 】

  • Tokyo Medical and Dental University, Faculty of Medicine, 2008.03, Graduated

To the head of this page.▲

Graduate School 【 display / non-display 】

  • Tokyo Medical and Dental University, Doctor's Course, 2018.03, Completed

To the head of this page.▲

Degree 【 display / non-display 】

  • Doctor of Philosophy in Medical Science, Tokyo Medical and Dental University

To the head of this page.▲

Campus Career 【 display / non-display 】

  • 2014.04
    -
    2018.03
    Tokyo Medical and Dental University， Graduate School of Medical and Dental Sciences， Medical and Dental Sciences， Advanced Therapeutic Sciences， Hematology， Graduate Student
  • 2019.04
    -
    2019.08
    Tokyo Medical and Dental University， (Old Organization)Medical Hospital， Hospital Departments， Department of Internal Medicine， Hematology， Assistant Professor
  • 2024.04
    -
    Now
    Tokyo Medical and Dental University， Tokyo Medical and Dental University， Division of Clinical Medicine， Department of Internal Medicine， Hematology， Project Assistant Professor
To the head of this page.▲

Academic Society Affiliations 【 display / non-display 】

  • The Japanese Society of Internal Medicine

  • The Japanese Society of Hematology

  • American Association for Cancer Research

  • The Japanese Cancer Association

  • American Society of Hematology

To the head of this page.▲
 

Published Papers & Misc 【 display / non-display 】

  1. Akiyama H, Kantarjian H, Jabbour E, Issa G, Haddad FG, Short NJ, Hu S, Ishizawa J, Andreeff M, Sasaki K. Outcome of 3q26.2/MECOM rearrangements in chronic myeloid leukemia. International journal of hematology. 2024.08; 120 (2): 203-211. ( PubMed, DOI )

  2. Pourebrahim R, Montoya RH, Akiyama H, Ostermann L, Khazaei S, Muftuoglu M, Baran N, Zhao R, Lesluyes T, Liu B, Khoury JD, Gagea M, Van Loo P, Andreeff M. Age-specific induction of mutant p53 drives clonal hematopoiesis and acute myeloid leukemia in adult mice. Cell reports. Medicine. 2024.05; 5 (5): 101558. ( PubMed, DOI )

  3. Akiyama H, Zhao R, Ostermann LB, Li Z, Tcheng M, Yazdani SJ, Moayed A, Pryor ML 2nd, Slngh S, Baran N, Ayoub E, Nishida Y, Mak PY, Ruvolo VR, Carter BZ, Schimmer AD, Andreeff M, Ishizawa J. Mitochondrial regulation of GPX4 inhibition-mediated ferroptosis in acute myeloid leukemia. Leukemia. 2024.04; 38 (4): 729-740. ( PubMed, DOI )

  4. Akiyama H, Zhao R, Ostermann LB, Li Z, Tcheng M, Yazdani SJ, Moayed A, Pryor ML 2nd, Slngh S, Baran N, Ayoub E, Nishida Y, Mak PY, Ruvolo VR, Carter BZ, Schimmer AD, Andreeff M, Ishizawa J. Correction: Mitochondrial regulation of GPX4 inhibition-mediated ferroptosis in acute myeloid leukemia. Leukemia. 2024.04; 38 (4): 926. ( PubMed, DOI )

  5. Akiyama H, Carter BZ, Andreeff M, Ishizawa J. Molecular Mechanisms of Ferroptosis and Updates of Ferroptosis Studies in Cancers and Leukemia. Cells. 2023.04; 12 (8): ( PubMed, DOI )

  6. Yasuda S, Aoyama S, Yoshimoto R, Li H, Watanabe D, Akiyama H, Yamamoto K, Fujiwara T, Najima Y, Doki N, Sakaida E, Edahiro Y, Imai M, Araki M, Komatsu N, Miura O, Kawamata N. MPL overexpression induces a high level of mutant-CALR/MPL complex: a novel mechanism of ruxolitinib resistance in myeloproliferative neoplasms with CALR mutations. International journal of hematology. 2021.10; 114 (4): 424-440. ( PubMed, DOI )

  7. Nishida Y, Zhao R, Heese LE, Akiyama H, Patel S, Jaeger AM, Jacamo RO, Kojima K, Ma MCJ, Ruvolo VR, Chachad D, Devine W, Lindquist S, Davis RE, Porco JA Jr, Whitesell L, Andreeff M, Ishizawa J. Inhibition of translation initiation factor eIF4a inactivates heat shock factor 1 (HSF1) and exerts anti-leukemia activity in AML. Leukemia. 2021.09; 35 (9): 2469-2481. ( PubMed, DOI )

  8. Akiyama, H; Umezawa, Y; Watanabe, D; Okada, K; Ishida, S; Nogami, A; Miura, O. Inhibition of USP9X Downregulates JAK2-V617F and Induces Apoptosis Synergistically with BH3 Mimetics Preferentially in Ruxolitinib-Persistent JAK2-V617F-Positive Leukemic Cells CANCERS. 2020.02; 12 (2): ( PubMed, DOI )

  9. Watanabe, D; Nogami, A; Okada, K; Akiyama, H; Umezawa, Y; Miura, O. FLT3-ITD Activates RSK1 to Enhance Proliferation and Survival of AML Cells by Activating mTORC1 and eIF4B Cooperatively with PIM or PI3K and by Inhibiting Bad and BIM CANCERS. 2019.12; 11 (12): ( PubMed, DOI )

  10. Akiyama, H; Umezawa, Y; Ishida, S; Okada, K; Nogami, A; Miura, O. Inhibition of USP9X induces apoptosis in FLT3-ITD-positive AML cells cooperatively by inhibiting the mutant kinase through aggresomal translocation and inducing oxidative stress CANCER LETTERS. 2019; 453 84-94. ( PubMed, DOI )

  11. Ayako Nogami, Keigo Okada, Shinya Ishida, Hiroki Akiyama, Yoshihiro Umezawa, Osamu Miura. Inhibition of the STAT5/Pim Kinase Axis Enhances Cytotoxic Effects of Proteasome Inhibitors on FLT3-ITD-Positive AML Cells by Cooperatively Inhibiting the mTORC1/4EBP1/S6K/Mcl-1 Pathway. Transl Oncol. 2018.11; 12 (2): 336-349. ( PubMed, DOI )

  12. Shinya Ishida, Hiroki Akiyama, Yoshihiro Umezawa, Keigo Okada, Ayako Nogami, Gaku Oshikawa, Toshikage Nagao, Osamu Miura. Mechanisms for mTORC1 activation and synergistic induction of apoptosis by ruxolitinib and BH3 mimetics or autophagy inhibitors in JAK2-V617F-expressing leukemic cells including newly established PVTL-2. Oncotarget. 2018.06; 9 (42): 26834-26851. ( PubMed, DOI )

  13. Okada K, Nogami A, Ishida S, Akiyama H, Chen C, Umezawa Y, Miura O. FLT3-ITD induces expression of Pim kinases through STAT5 to confer resistance to the PI3K/Akt pathway inhibitors on leukemic cells by enhancing the mTORC1/Mcl-1 pathway. Oncotarget. 2018.02; 9 (10): 8870-8886. ( PubMed, DOI )

  14. Keigo Okada, Ayako Nogami, Shinya Ishida, Hiroki Akiyama, Cheng Chen, Yoshihiro Umezawa and Osamu Miura. FLT3-ITD induces expression of Pim kinases through STAT5 to confer resistance to the PI3K/Akt pathway inhibitors on leukemic cells by enhancing the mTORC1/Mcl-1 pathway Oncotarget. 2017.12; 9 8870-8886.

  15. Yoshihiro Umezawa, Hiroki Akiyama, Keigo Okada, Shinya Ishida, Ayako Nogami, Gaku Oshikawa, Tetsuya Kurosu, Osamu Miura. Molecular mechanisms for enhancement of stromal cell-derived factor 1-induced chemotaxis by platelet endothelial cell adhesion molecule 1 (PECAM-1). Journal of Biological Chemistry. 2017.12; 292 (48): 19639-19655.

  16. Umezawa, Y; Akiyama, H; Okada, K; Ishida, S; Nogami, A; Oshikawa, G; Kurosu, T; Miura, O. Molecular mechanisms for enhancement of stromal cell-derived factor 1-induced chemotaxis by platelet endothelial cell adhesion molecule 1 (PECAM-1) JOURNAL OF BIOLOGICAL CHEMISTRY. 2017.12; 292 (48): 19639-19655. ( PubMed, DOI )

  17. Tanaka, K; Oshikawa, G; Akiyama, H; Ishida, S; Nagao, T; Yamamoto, M; Miura, O. Acute myeloid leukemia with t(3;21)(q26.2;q22) developing following low-dose methotrexate therapy for rheumatoid arthritis and expressing two AML1/MDS1/EVI1 fusion proteins: A case report ONCOLOGY LETTERS. 2017.07; 14 (1): 97-102. ( PubMed, DOI )

  18. Hiroki Akiyama, Hiroshi Takase, Fumito Kubo, Tohru Miki, Masahide Yamamoto, Makoto Tomita, Manabu Mochizuki, Osamu Miura, Ayako Arai. High-dose methotrexate following intravitreal methotrexate administration in preventing central nervous system involvement of primary intraocular lymphoma. Cancer Science. 2016.10; 107 (10): 1458-1464. ( PubMed, DOI )

  19. Yoshihiro Umezawa, Tetsuya Kurosu, Hiroki Akiyama, Nang Wu, Ayako Nogami, Toshikage Nagao, Osamu Miusa. Down regulation of Chk1 by p53 plays a role in synergistic induction of apoptosis by chemotherapeutics and inhibitors for Jak2 or BCR/ABL in hematopoietic cells. Oncotarget. 2016.06; ( PubMed )

  20. Masahide Yamamoto, Keigo Okada, Hiroki Akiyama, Tetsuya Kurosu, Osamu Miura. Evaluation of the efficacy of maintenance therapy for low-to-intermediate-risk acute promyelocytic leukemia in molecular remission: A retrospective single-institution study. Mol Clin Oncol. 2015.03; 3 (2): 449-453. ( PubMed, DOI )

  21. Hiroki Akiyama, Masahide Yamamoto, Chizuko Sakashita, Yoshihiro Umezawa, Tetsuya Kurosu, Naomi Murakami, Osamu Miura. Therapy-related Leukemia with Inv(16)(p13.1q22) and Type D CBFB/MYH11 Developing after Exposure to Irinotecan-containing Chemoradiotherapy. Intern. Med.. 2015; 54 (6): 651-655. ( PubMed, DOI )

▼display all

To the head of this page.▲

Conference Activities & Talks 【 display / non-display 】

  1. 石澤 丈, 秋山 弘樹, 大槻 雄士, Zhao Ran, Yazdani Samar, Moayed Arman, 西田 有毅, Ayoub Edward, Ostermann Lauren, Carter Bing, 佐谷 秀行, 永野 修, Andreeff Michael. アルデヒド代謝阻害によるミトコンドリア依存性フェロトーシス増強効果を活用した急性骨髄性白血病治療戦略. 日本血液学会学術集会 2023.10.01

  2. 秋山 弘樹, Zhao Ran, Rahhal Adam, 西田 有毅, Ayoub Edward, Ostermann Lauren, Andreeff Michael, 石澤 丈. セレノプロテインGPX4阻害およびミトコンドリアプロテアーゼCLPP活性化による相乗的抗白血病効果(Dual targeting of selenoprotein GPX4 and mitochondrial ClpP causes synergistic anti-leukemia effects). 日本血液学会学術集会 2021.09.01

  3. Hiroki Akiyama, Ishizawa Jo. Glutathione-GPX4 NexusはミトコンドリアプロテアーゼClpP誘発性の細胞傷害から急性骨髄性白血病(AML)細胞を保護する(Glutathione-GPX4 Nexus Protects Acute Myeloid Leukemia(AML) Cells From Mitochondrial Protease ClpP-induced Cell Killing). 日本癌学会総会記事 2021.09.01

  4. 青山 慧, 安田 俊一郎, 李 慧欣, 渡邉 大介, 秋山 弘樹, 岡田 啓五, 梅澤 佳央, 野上 彩子, 三浦 修, 川又 紀彦. プロテアーゼによる蛋白切断を介した新規の制御型CARによるCAR-T細胞の標的特異性の改善(Protease mediated regulatory chimeric antigen receptor(CAR) improves target specificity). 日本血液学会学術集会 2021.09.01

  5. Ayako Nogami, Watanabe Daisuke, Keigo Okada, Hiroki Akiyama, Yoshihiro Umezawa, Toshikage Nagao, Shuji Tohdaand Osamu Miura. FLT3-ITD Enhances Proliferation and Survival of AML Cells through Activation of RSK1 to Upregulate the mTORC1/eIF4F Pathway Cooperatively with PIM or PI3K and to Inhibit Bad and Bim. 60th ASH Annual Meeting and Exposition 2019.12.01 FL, Orange County Convention Center

  6. Hiroki Akiyama, Yoshihiro Umezawa, Keigo Okada, Daisuke Watanabe, Shinya Ishida, Ayako Nogami, Osamu Miura. Deubiquitinase Inhibitor WP1130 Exerts Anti-leukemic Effect by Causing Aggresomal Translocation of FLT3-ITD and Oxidative Stress to Induce Apoptosis. The 9th JSH International Symposium 2018 2018.07.27 Kyoto

  7. Hiroki Akiyama, Yoshihiro Umezawa, Keigo Okada, Shinya Ishida, Ayako Nogami, and Osamu Miura. Deubiquitinase Inhibitor WP1130 Blocks FLT3-ITD to Induce Apoptosis in Leukemic Cells. The 59th American Society of Hematology Annual Meeting & Exposition 2017.12.10 Atlanta

  8. Keigo Okada, Ayako Nogami, Cheng Chen, Maho kawakami, Hiroki Akiyama, Shinya Ishida, Yoshihiro Umezawa, Osamu Miura. FLT3-ITD confers resistance to PI3K/Akt inhibitors by enhancing mTORC1/Mcl-1 pathway via Pim kinase. 第79回日本血液学会学術集会 2017.10.20

  9. Okada Keigo, Nogami Ayako, Chen Cheng, Kawakami Maho, Akiyama Hiroki, Ishida Shinya, Umezawa Yoshihiro, Miura Osamu. FLT3-ITDのPimキナーゼによるmTOR経路促進を介したPI3K/Akt阻害薬への耐性獲得機構(FLT3-ITD confers resistance to PI3K/Akt inhibitors by enhancing mTORC1/Mcl-1 pathway via Pim kinase). 臨床血液 2017.09.01

  10. Akiyama Hiroki, Umezawa Yoshihiro, Okada Keigo, Ishida Shinya, Nogami Ayako, Nagao Toshikage, Miura Osamu. 脱ユビチキン化酵素阻害剤WP1130によるJAK2-V617の抑制と抗白血病効果(Deubiquitinase inhibitor WP1130 blocks JAK2-V617F to induce apoptosis in leukemic cells). 臨床血液 2017.09.01

  11. Saito Tatsuya, Tsutsumi Hiroki, Yamashita Tomoko, Akiyama Hiroki, Umezawa Yoshihiro, Watanabe Ken, Fukuda Tetsuya, Kawamata Norihiko, Miura Osamu, Yamamoto Masahide. 抗ヒト胸腺細胞ウサギ免疫グロブリンにて治療した造血不全患者のウイルスモニタリング(Viral monitoring using multiplex PCR in patients with bone marrow failure treated with rabbit ATG). 臨床血液 2017.09.01

  12. Ishida Shinya, Nagao Toshikage, Okada Keigo, Akiyama Hiroki, Umezawa Yoshihiro, Nogami Ayako, Miura Osamu. JAK2-V617陽性細胞のオートファジーとBcl2ファミリーによるruxolitinib耐性機構(Autophagy and Bcl-2 family members protect JAK2-V617F-expressing leukemic cells from ruxolitinib). 臨床血液 2017.09.01

  13. Nogami Ayako, Okada Keigo, Chen Cheng, Kawakami Maho, Akiyama Hiroki, Umezawa Yoshihiro, Ishida Shinya, Miura Osamu. FLT3-ITD陽性白血病細胞におけるmTORC1シグナルのUPSによる制御機構とREDD1の関与(Modulation of the mTORC1 pathway by ubiquitin-proteasome system via REDD1 in AML with FLT3-ITD). 臨床血液 2017.09.01

  14. Ayako Nogami, Keigo Okada, Gaku Oshikawa, Shinya Ishida, Hiroki Akiyama, Yoshihiro Umezawa,Tetsuya Kurosu,Osamu Miura. FLT3-ITD Confers Resistance to Bortezomib By Protecting the mTOR/4EBP1 Pathway through Activation of STAT5 and Induction of Pim-1 Expression. 57th ASH Annual Meeting and Exposition 2015.12.05 Orange County Convention Center, Orlando

  15. Ayako Arai, Hiroshi Takase, Kouhei Yamamoto, Hiroki Akiyama, Manabu Mochizuki, Osamu Miura. Gene expression profiling of primary vitreoretinal lymphoma. 57th ASH Annual Meeting and Exposition 2015.12.05 Orlando

  16. Keigo Okada, Ayako Nogami, Gaku Oshikawa, Shinya Ishida, Hiroki Akiyama, Yoshihiro Umezawa, Osamu Miura. FLT3-ITD confers resistance to PI3K/Akt inhibitors by inducing Pim kinases through STAT5 activation. 第77回日本血液学会学術集会 2015.10.18

  17. Yoshihiro Umezawa, Hiroki Akiyama, Keigo Okada, Shinya Ishida, Ayako Nogami, Gaku Oshikawa, Tetsuya Kurosu, Osamu Miura. PECAM−1 enhances SDF-1-induced chemotaxis mediated through activation of the PI3K/Akt/mTORC1 pathway. The 77th annual meeting of the japanese society of hematology 2015.10.17

  18. 野上　彩子、岡田　啓五、押川　学、石田　信也、秋山　弘樹、梅澤　佳央、黒須　哲也、三浦　修. FLT3-ITDによるSTAT5、Pim-1と mTOR経路を介したBortezomib耐性誘導機構. 第77回日本血液学会学術集会 2015.10.16 石川県立音楽堂

  19. Ayako Nogami, Gaku Oshikawa, Shinya Ishida, Hiroki Akiyama, Yoshihiro Umezawa, Toshikage Nagao, Tetsuya Kurosu, Osamu Miura. FLT3-ITD confers resistance to PI3K/Akt inhibitors by protecting mTOR/eIF4F/Mcl-1 pathway via STAT5. 第76回日本血液学会月術集会 2014.10.31 Osaka

▼display all

To the head of this page.▲